PMID- 34940343
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 2306-5354 (Print)
IS  - 2306-5354 (Electronic)
IS  - 2306-5354 (Linking)
VI  - 8
IP  - 12
DP  - 2021 Nov 23
TI  - Preclinical Efficacy of Pro- and Anti-Angiogenic Peptide Hydrogels to Treat 
      Age-Related Macular Degeneration.
LID - 10.3390/bioengineering8120190 [doi]
LID - 190
AB  - Pro-angiogenic and anti-angiogenic peptide hydrogels were evaluated against the 
      standard of care wet age-related macular degeneration (AMD) therapy, Aflibercept 
      (Eylea((R))). AMD was modeled in rats (laser-induced choroidal neovascularization 
      (CNV) model), where the contralateral eye served as the control. After 
      administration of therapeutics, vasculature was monitored for 14 days to evaluate 
      leakiness. Rats were treated with either a low or high concentration of 
      anti-angiogenic peptide hydrogel (0.02 wt% 8 rats, 0.2 wt% 6 rats), or a 
      pro-angiogenic peptide hydrogel (1.0 wt% 7 rats). As controls, six rats were 
      treated with commercially available Aflibercept and six with sucrose solution 
      (vehicle control). Post lasering, efficacy was determined over 14 days via 
      fluorescein angiography (FA) and spectral-domain optical coherence tomography 
      (SD-OCT). Before and after treatment, the average areas of vascular leak per 
      lesion were evaluated as well as the overall vessel leakiness. Unexpectedly, 
      treatment with pro-angiogenic peptide hydrogel showed significant, immediate 
      improvement in reducing vascular leak; in the short term, the pro-angiogenic 
      peptide performed better than anti-angiogenic peptide hydrogel and was comparable 
      to Aflibercept. After 14 days, both the pro-angiogenic and anti-angiogenic 
      peptide hydrogels show a trend of improvement, comparable to Aflibercept. Based 
      on our results, both anti-angiogenic and pro-angiogenic peptide hydrogels may 
      prove good therapeutics in the future to treat wet AMD over a longer-term 
      treatment period.
FAU - Acevedo-Jake, Amanda
AU  - Acevedo-Jake A
AD  - Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, 
      NJ 07102, USA.
FAU - Shi, Siyu
AU  - Shi S
AD  - Stanford School of Medicine, Stanford University, Stanford, CA 94305, USA.
FAU - Siddiqui, Zain
AU  - Siddiqui Z
AD  - Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, 
      NJ 07102, USA.
FAU - Sanyal, Sreya
AU  - Sanyal S
AD  - Department of Biology, New Jersey Institute of Technology, Newark, NJ 07102, USA.
FAU - Schur, Rebecca
AU  - Schur R
AD  - Cole Eye Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, OH 
      44195, USA.
FAU - Kaja, Simon
AU  - Kaja S
AD  - Research & Development Division, Experimentica Ltd., 70211 Kuopio, Finland.
AD  - Department of Ophthalmology, Loyola University Chicago, Maywood, IL 60153, USA.
FAU - Yuan, Alex
AU  - Yuan A
AD  - Cole Eye Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, OH 
      44195, USA.
FAU - Kumar, Vivek A
AU  - Kumar VA
AUID- ORCID: 0000-0001-7536-9281
AD  - Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, 
      NJ 07102, USA.
AD  - Department of Biology, New Jersey Institute of Technology, Newark, NJ 07102, USA.
AD  - Department of Chemical Engineering, New Jersey Institute of Technology, Newark, 
      NJ 07102, USA.
AD  - Department of Restorative Dentistry, Rutgers School of Dental Medicine, Newark, 
      NJ 07102, USA.
LA  - eng
GR  - EY029504/National Institute of Health/
GR  - 1903617/National Science Foundation/
PT  - Journal Article
DEP - 20211123
PL  - Switzerland
TA  - Bioengineering (Basel)
JT  - Bioengineering (Basel, Switzerland)
JID - 101676056
PMC - PMC8698576
OTO - NOTNLM
OT  - anti-angiogenic
OT  - biomaterials
OT  - hydrogel
OT  - multi-functional scaffolds
OT  - pro-angiogenic
OT  - tissue regeneration
OT  - wet age-related macular degeneration
COIS- V.A.K. has equity interests in start-up companies attempting to translate 
      peptides from this technological platform.
EDAT- 2021/12/24 06:00
MHDA- 2021/12/24 06:01
PMCR- 2021/11/23
CRDT- 2021/12/23 12:43
PHST- 2021/09/19 00:00 [received]
PHST- 2021/11/20 00:00 [revised]
PHST- 2021/11/21 00:00 [accepted]
PHST- 2021/12/23 12:43 [entrez]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2021/12/24 06:01 [medline]
PHST- 2021/11/23 00:00 [pmc-release]
AID - bioengineering8120190 [pii]
AID - bioengineering-08-00190 [pii]
AID - 10.3390/bioengineering8120190 [doi]
PST - epublish
SO  - Bioengineering (Basel). 2021 Nov 23;8(12):190. doi: 
      10.3390/bioengineering8120190.